#USA #Pittsburgh #Catalyst MedTech #Connect Program #Algernon Pharmaceuticals

Catalyst MedTech Launches the Connect Program

Catalyst MedTech, a key player in the medical imaging field, has recently unveiled its new initiative known as the Connect program, which is designed to shape a collaborative environment focused on advancing patient care through improved access to diagnostic imaging. This innovative program aims to harness the company’s unique dual business structure, consisting of Equipment Solutions and Clinical Solutions, to deliver tailored pathways for enhanced imaging accessibility.

The Connect program not only promotes collaboration among healthcare professionals but also ensures that groundbreaking innovations in imaging can effectively reach the patients who need it. Central to this initiative is the announcement of a partnership with Algernon Pharmaceuticals Inc., a Canada-based healthcare company that aims to expand access to Optimized Brain Positron Emission Tomography (PET) imaging across the United States. This partnership marks a significant step towards establishing a dedicated network of neuroimaging medical clinics, which will facilitate the early detection of Alzheimer's and other neurologic conditions.

Algernon Pharmaceuticals, through the Connect initiative, is set to establish its first neuroimaging clinics in the U.S., thereby creating a dedicated framework for early-stage Alzheimer's detection. To power this initiative, Catalyst MedTech will provide a comprehensive mix of equipment, services, and ongoing support, including the advanced Optimized Brain PET imaging solution, which integrates their CareMiBrain™ technology with the NeuroQ® advanced quantitative workstation.

Martin B. Shirley, CEO and President of Catalyst MedTech, expressed the importance of the Connect program by stating, “The vision of Connect is to help finish the story for our partners. Many companies want to create an impact in specific areas—be it neurology, cardiology, or beyond. Catalyst acts as the connector that transforms these ambitions into reality by providing the necessary access, expertise, and solutions, thereby bridging the gap between vision and execution.”

In the context of millions of individuals being at risk for Alzheimer’s disease and related disorders, the significance of Brain PET imaging is becoming increasingly prominent as it stands as a standard for achieving earlier and more confident diagnoses. The optimized CareMiBrain™ system, which Catalyst MedTech exclusively distributes in the U.S., sets a new benchmark within neurologic imaging, featuring ultra-high resolution imaging in a compact, patient-centered design, alongside an advanced quantitative neurologic workstation. This combination allows for both diagnostic precision and practical scalability across various medical settings, such as neurology practices, imaging centers, and hospitals.

Christopher J. Moreau, CEO of Algernon Pharmaceuticals, also shared his enthusiasm for the partnership, stating, “We are very excited to be working with Catalyst MedTech to accelerate access to Brain PET in the U.S. Catalyst's ability to connect the dots between innovation, accessibility, and patient care aligns perfectly with our mission to construct a network of advanced neuroimaging clinics. Together, we can significantly improve diagnosis and treatment for patients suffering from Alzheimer’s and other neurodegenerative conditions.”

Catalyst MedTech continues to position itself at the forefront of advanced imaging, facilitating pathways for adoption that ensure technological breakthroughs translate into enhanced patient care, expedited answers, and improved healthcare outcomes. The company's commitment to delivering value through advanced diagnostic imaging and therapies signifies its dedication to providing essential care for patients.

About Catalyst MedTech

Catalyst MedTech excels as a nationwide provider of nuclear medicine, molecular imaging, and CT solutions. Their mission centers around delivering value and accessibility through advanced diagnostic imaging and related therapies to ensure that patients receive the necessary care and treatments they require.

Possessing OEM-trained service teams and clinical expertise, along with a versatile equipment portfolio, Catalyst MedTech supports providers in various medical domains, including cardiology and neurology. As an OEM and the largest independent ISO-certified service provider for nuclear medicine and molecular imaging in the U.S., Catalyst MedTech is dedicated to aiding healthcare organizations in achieving quicker diagnosis, strengthened confidence, and better patient outcomes.

For additional details about Catalyst MedTech, visit www.catalystmedtech.com.

About Algernon Pharmaceuticals

Algernon Pharmaceuticals is a Canadian healthcare company focused on the provision of brain-specific PET scanning services. They aim to create a network of new clinics in North America for the early detection of Alzheimer's disease, as well as other dementias, epilepsy, neuro-oncology, and movement disorders. Furthermore, Algernon operates a private subsidiary called Algernon NeuroScience, which is investigating a proprietary form of DMT for stroke and traumatic brain injuries.

For more information about Algernon Pharmaceuticals, please visit www.algernonpharmaceuticals.com.